We are live on
!
Find out more
SGAM
Smith Group Asset Management Portfolio holdings
AUM
$2.46B
Turnover
25.53%
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter
Est. Return
+9.07%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
+$161M
(+6%)
Cap. Flow
-$2.69M
Cap. Flow
% of AUM
-0.09%
Top 10 Holdings %
Top 10 Hldgs %
25.36%
Holding
465
New
60
Increased
102
Reduced
122
Closed
47
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cboe Global Markets
CBOE
|
+$33.3M |
| 2 |
Apple
AAPL
|
+$32.7M |
| 3 |
Landstar System
LSTR
|
+$31.2M |
| 4 |
Gartner
IT
|
+$30.5M |
| 5 |
Bath & Body Works
BBWI
|
+$28.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SANDISK CORP
SNDK
|
+$54.1M |
| 2 |
Affiliated Managers Group
AMG
|
+$31.4M |
| 3 |
Booking.com
BKNG
|
+$26.9M |
| 4 |
IDEX
IEX
|
+$25.5M |
| 5 |
Hormel Foods
HRL
|
+$21.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.8% |
| 2 | Healthcare | 16.57% |
| 3 | Industrials | 13.8% |
| 4 | Consumer Discretionary | 12.79% |
| 5 | Financials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
DHI Group
DHX
$209M
| $1.1M | 0.04% |
+109,700
| New | +$1.08M |
2014 Q4
0 quarters
|
|
177
DELISTED
Xoma
XOMA
| $1.09M | 0.04% |
15,238
-1,526
| -9% | -$131K |
2014 Q2
2 quarters
|
|
178
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.09M | 0.04% |
+3,056
| New | +$910K |
2014 Q4
0 quarters
|
|
179
Alaunos Therapeutics
TCRT
$6.48M
| $1.09M | 0.04% |
1,433
-144
| -9% | -$76.4K |
2014 Q1
3 quarters
|
|
180
Prothena Corp
PRTA
$428M
| $1.09M | 0.04% |
52,350
+50,880
| +3,461% | +$1.06M |
2014 Q3
1 quarter
|
|
181
BGC Group
BGC
$5.38B
| $979K | 0.03% |
+166,369
| New | +$893K |
2014 Q4
0 quarters
|
|
182
Verastem
VSTM
$782M
| $976K | 0.03% |
8,898
-885
| -9% | -$95.7K |
2013 Q4
4 quarters
|
|
|
XLRN
183
DELISTED
Acceleron Pharma
XLRN
| $970K | 0.03% |
24,890
-2,510
| -9% | -$87.5K |
2014 Q3
1 quarter
|
|
|
AMSG
184
DELISTED
Amsurg Corp
AMSG
| $953K | 0.03% |
17,417
+4,010
| +30% | +$204K |
2014 Q3
1 quarter
|
|
|
SWC
185
DELISTED
Stillwater Mining Co
SWC
| $942K | 0.03% |
63,900
-6,500
| -9% | -$89.2K |
2014 Q2
2 quarters
|
|
|
SCAI
186
DELISTED
Surgical Care Affiliates, Inc.
SCAI
| $854K | 0.03% |
+25,390
| New | +$782K |
2014 Q4
0 quarters
|
|
|
NTUS
187
DELISTED
Natus Medical Inc
NTUS
| $850K | 0.03% |
+23,590
| New | +$792K |
2014 Q4
0 quarters
|
|
|
BAS
188
DELISTED
Basis Energy Services, Inc.
BAS
| $841K | 0.03% |
211
-20
| -9% | -$126K |
2014 Q2
2 quarters
|
|
|
SPPI
189
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $838K | 0.03% |
+120,950
| New | +$889K |
2014 Q4
0 quarters
|
|
190
Madrigal Pharmaceuticals
MDGL
$10.4B
| $773K | 0.03% |
8,339
-830
| -9% | -$85.8K |
2014 Q3
1 quarter
|
|
191
Inovio Pharmaceuticals
INO
$102M
| $749K | 0.03% |
6,799
-684
| -9% | -$83.6K |
2014 Q2
2 quarters
|
|
192
Lexicon Pharmaceuticals
LXRX
$676M
| $735K | 0.03% |
+115,409
| New | +$930K |
2014 Q4
0 quarters
|
|
193
Usana Health Sciences
USNA
$285M
| $731K | 0.03% |
+14,260
| New | +$700K |
2014 Q4
0 quarters
|
|
194
Boise Cascade
BCC
$2.66B
| $729K | 0.03% |
19,615
-1,486
| -7% | -$51.2K |
2014 Q3
1 quarter
|
|
|
NAVG
195
DELISTED
Navigators Group Inc
NAVG
| $718K | 0.03% |
19,586
-1,800
| -8% | -$62.1K |
2013 Q2
6 quarters
|
|
|
HPTX
196
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $698K | 0.02% |
29,100
-2,900
| -9% | -$65.4K |
2014 Q2
2 quarters
|
|
|
SYKE
197
DELISTED
SYKES Enterprises Inc
SYKE
| $695K | 0.02% |
29,619
-2,281
| -7% | -$51K |
2014 Q2
2 quarters
|
|
|
AFFX
198
DELISTED
Affymetrix Inc
AFFX
| $668K | 0.02% |
67,770
+62,270
| +1,132% | +$544K |
2014 Q2
2 quarters
|
|
199
DELISTED
Immunogen Inc
IMGN
| $597K | 0.02% |
97,860
-9,410
| -9% | -$86.1K |
2014 Q3
1 quarter
|
|
|
ALJ
200
DELISTED
Alon USA Energy Inc
ALJ
| $591K | 0.02% |
+46,711
| New | +$671K |
2014 Q4
0 quarters
|
|
Similar funds
MAMU
PC
RG
DIA
Smith Group Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, Smith Group Asset Management held 465 positions worth $2.86B, up 6% from $2.7B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Smith Group Asset Management's Q4 2014 filing shows 60 new, 102 increased, 122 reduced and 47 closed positions. Its largest new stake was Cboe Global Markets: 558,100 shares worth $35.4M. The largest sale was SANDISK CORP, an estimated $54.1M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
- Smith Group Asset Management's largest Q4 2014 buy was Cboe Global Markets: 558,100 shares worth $35.4M.
- Smith Group Asset Management added most to Apple in Q4 2014, an estimated $32.7M increase.
- Smith Group Asset Management's biggest Q4 2014 reduction was Kimberly-Clark, cutting an estimated $15.6M.
- Smith Group Asset Management fully exited SANDISK CORP in Q4 2014, selling an estimated $54.1M.
- Smith Group Asset Management's ten largest holdings make up 25% of its $2.86B portfolio in Q4 2014.
- Smith Group Asset Management opened 60 new positions and closed 47 in Q4 2014.
- Smith Group Asset Management's portfolio value rose 6% quarter-over-quarter to $2.86B.
Based on Smith Group Asset Management's 13F filing for Q4 2014, filed 27 Jan 2015.